https://scientific-jl.com/luch/
Часть-39_ Том-1_ Февраль-2025
142
MODERN DIAGNOSTIC METHODS OF SYSTEMIC LUPUS
ERYTHEMATOSUS
Khamraev Botirjon
Samarkand State Medical University
Abstract: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune
disease characterized by multisystem involvement and a wide range of clinical
manifestations. Early and accurate diagnosis of SLE is crucial for effective
management and prevention of complications. Over the years, significant
advancements have been made in diagnostic techniques, including serological
markers, imaging modalities, and genetic testing. This article explores the modern
diagnostic methods for SLE, focusing on their accuracy, accessibility, and clinical
relevance.
Keywords: systemic lupus erythematosus, autoimmune disease, diagnosis,
serological markers, imaging, genetic testing
INTRODUCTION
Systemic Lupus Erythematosus (SLE) is an autoimmune disease that affects
multiple organs, including the skin, kidneys, joints, and the central nervous system.
Due to its diverse clinical presentation, diagnosing SLE remains a challenge for
healthcare professionals. Traditional diagnostic criteria, such as the American
College of Rheumatology (ACR) and Systemic Lupus International Collaborating
Clinics (SLICC) classification, have been widely used. However, modern
advancements have introduced more precise diagnostic tools that enhance early
detection and disease monitoring.
The pathogenesis of SLE is complex and involves genetic, environmental, and
hormonal factors. Genetic predisposition plays a crucial role, with certain human
https://scientific-jl.com/luch/
Часть-39_ Том-1_ Февраль-2025
143
leukocyte antigen (HLA) genes being strongly associated with SLE development.
Environmental triggers, such as ultraviolet (UV) radiation, infections, and certain
medications, can lead to immune system dysregulation in genetically susceptible
individuals. Hormonal influences, particularly the role of estrogen, contribute to
the higher prevalence of SLE in females compared to males.
Early diagnosis of SLE is critical for preventing organ damage and improving
patient outcomes. However, the disease's heterogeneous nature often leads to
delays in diagnosis. Symptoms such as fatigue, joint pain, skin rashes, and fever
can overlap with other autoimmune disorders, making differential diagnosis
essential. Advances in diagnostic techniques have aimed to improve accuracy and
reduce misdiagnosis.
Recent research has also focused on identifying new biomarkers for SLE.
These biomarkers aid in early disease detection, assessing disease activity, and
predicting flares. In addition to traditional serological markers, novel biomarkers
such as interferon signatures, microRNAs, and metabolic profiles are being
investigated for their diagnostic potential. The integration of these advanced tools
into clinical practice will likely enhance diagnostic precision and facilitate
personalized treatment approaches.
Serological Markers in SLE Diagnosis
One of the most important aspects of SLE diagnosis is the identification of
specific autoantibodies. Antinuclear antibodies (ANA) serve as a primary
screening tool, as they are present in nearly all SLE patients. More specific markers,
such as anti-dsDNA and anti-Smith (Sm) antibodies, are crucial in confirming the
diagnosis. Other serological markers, including complement levels (C3, C4) and
antiphospholipid antibodies, provide additional information about disease activity
and associated complications.
https://scientific-jl.com/luch/
Часть-39_ Том-1_ Февраль-2025
144
Advanced imaging methods play a critical role in assessing organ involvement
in SLE. Magnetic resonance imaging (MRI) and computed tomography (CT) scans
help evaluate central nervous system manifestations, while ultrasound and Doppler
imaging are valuable in detecting vascular complications. Furthermore, positron
emission tomography (PET) scans have been increasingly utilized to assess
inflammatory activity in various organs.
Genetic and Molecular Diagnostics
Recent advancements in genetic testing have improved our understanding of
the hereditary factors contributing to SLE. Genome-wide association studies
(GWAS) have identified multiple susceptibility genes, such as HLA-DR2 and
HLA-DR3. Additionally, epigenetic modifications, including DNA methylation
patterns, have been investigated for their role in SLE pathogenesis. These
molecular techniques contribute to personalized treatment strategies and early risk
assessment.
CONCLUSION
Modern diagnostic methods have significantly enhanced the early detection
and accurate classification of SLE. Serological markers, imaging techniques, and
genetic studies provide valuable insights into disease progression and severity. As
research continues to advance, integrating these diagnostic modalities will lead to
better disease management and improved patient outcomes.
REFERENCES:
1. Tsokos, G. C. (2011). Systemic lupus erythematosus. New England Journal
of Medicine, 365(22), 2110-2121.
2. Petri, M., Orbai, A. M., Alarcón, G. S., Gordon, C., Merrill, J. T., Fortin, P.
R., ... & Costenbader, K. H. (2019). Derivation and validation of the Systemic
https://scientific-jl.com/luch/
Часть-39_ Том-1_ Февраль-2025
145
Lupus International Collaborating Clinics classification criteria for SLE. Arthritis
& Rheumatology, 71(9), 1400-1412.
3. Aringer, M., Costenbader, K., Daikh, D., Brinks, R., Mosca, M., Ramsey-
Goldman, R., ... & Johnson, S. R. (2019). 2019 European League Against
Rheumatism/American College of Rheumatology classification criteria for
systemic lupus erythematosus. Annals of the Rheumatic Diseases, 78(9), 1151-
1159.
4. Pisetsky, D. S., & Lipsky, P. E. (2020). New insights into the role of
antinuclear antibodies in systemic lupus erythematosus. Nature Reviews
Rheumatology, 16(10), 565-579.
5. Wallace, D. J., & Hahn, B. H. (Eds.). (2019). Dubois' lupus erythematosus
and related syndromes. Elsevier Health Sciences.
6. Bertsias, G., Ioannidis, J. P., Boletis, J., Bombardieri, S., Cervera, R.,
Dostal, C., ... & Boumpas, D. T. (2008). EULAR recommendations for the
management
of
systemic
lupus
erythematosus
with
neuropsychiatric
manifestations: report of a task force of the EULAR standing committee for clinical
affairs. Annals of the Rheumatic Diseases, 67(5), 687-696.
7. Gatto, M., Zen, M., Iaccarino, L., & Doria, A. (2013). Emerging and critical
issues in the pathogenesis of lupus. Autoimmunity Reviews, 12(4), 523-536.
8. Choi, J., & Kim, S. T. (2017). Biomarkers of systemic lupus erythematosus:
cytokines, chemokines, and interferons. Clinical and Experimental Rheumatology,
35(4), 561-570.
a
